Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
8 participants
OBSERVATIONAL
2018-01-02
2019-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cerebral Desaturation in Traumatic Brain Injury
NCT02810145
Brain Injury Assessment Study at Hennepin County Medical Center
NCT02706574
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
NCT06103201
Multiomic Analysis of Serum in Acute Period of Traumatic Brain Injury
NCT05867992
Platelet Bioenergetics in TBI
NCT04271059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All adult participants with a primary diagnosis of severe, non-penetrating TBI or aSAH who are admitted to the neuroscience or trauma intensive care units will be screened for potential inclusion into this study. Once a potential participant is identified, the legally-authorized representative will be approached for study consent and HIPAA authorization. If the participant regains consent capacity before the end of the cerebrospinal fluid (CSF) collection period, assent will be obtained from the research participant.
In this research study, up to 5 small samples of CSF, will be carefully removed from the device, already in place, that drains excess CSF from the participant's head. The samples will be less than 1 teaspoon (\< 5 mL) each. These samples will be frozen and stored until samples from approximately 20 participants have been obtained.
These samples will then be prepared and sent to a research laboratory to analyze the proteins in the samples collected from each research participant.
Because the results of this study will not affect the treatment participants receive in or outside of the hospital, the investigator will not share the results of this study with the participant, their doctor or their family member(s).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* must have a ventriculostomy (EVD) placed by the UK Neurosurgery service within 12 hours of primary traumatic episode
Exclusion Criteria
* life expectancy is five days or less
* penetrating TBI
* status epilepticus upon arrival to the hospital
* severe ischemic heart disease or congestive heart failure, myocardial infarction, or spinal cord injury
* Takotsubo cardiomyopathy secondary to the SAH
* active cancer or have been treated for cancer within the previous 6 months
18 Years
101 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Kentucky
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Linda Van Eldik
Sponsor Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda J Van Eldik, PhD
Role: STUDY_DIRECTOR
University of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kentucky Deparment of Neurosurgery, UK Chandler Hospital
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-0583-F6A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.